

VP-DJ Shariah China A-Shares 100 ETF



NOVEMBER 2024 Currency: MYR

Stock code: 0838EA

Price: MYR 1.1500

INVESTMENT OBJECTIVE

The Fund aims to provide investment results that closely correspond to the performance of the Benchmark.

INVESTMENT STRATEGY

The Manager intends to primarily use a full replication strategy through investing in Shariah-compliant A-Shares that are included in the Benchmark, having substantially the same weightings in which they are included in the Benchmark.

FUND INFORMATION

Manager	M & A Value Partners Asset Management Malaysia Sdn. Bhd.
Trustee	CIMB Islamic Trustee Bhd
Shariah Adviser	Amanie Advisors Sdn Bhd
Country of Domicile	Malaysia
Asset Class	Equity
Launch Date	12 July 2021
Listing Date	28 July 2021
Fund Size (MYR)	31.84 mln
NAV per Unit (MYR)	1.1372
Distribution policy	Incidental

BENCHMARK

Dow Jones Islamic Market China A-Shares 100 Index

FEES & CHARGES

Management fee:

Up to 0.60% p.a. of the NAV of the Fund.

Trustee fee:

Up to 0.06% p.a. of the NAV of the Fund, subject to a minimum of MYR12,000 p.a.

Index license fee:

Up to 0.04% p.a. of the NAV of the Fund, subject to a minimum of USD15,000 p.a.

All data as at 29-Nov-2024 unless otherwise stated.

FUND PERFORMANCE




(%)	1-Month	3-Month	6-Month	Year-to-Date
Fund	-1.1	17.2	3.7	4.7
Benchmark	-0.3	18.2	5.2	6.8


(%)	1-Year*	3-Year*	5-Year*	Since Inception*
Fund	2.4	-16.2	n.a	-15.4
Benchmark	4.6	-15.1	2.9	-14.3

* Return for more than 1 year period is annualised. Performance is calculated based on Bloomberg. Benchmark performance returns do not reflect any management fees, transaction

ASSET CLASS ALLOCATION[^]



SECTOR ALLOCATION[^]



[^] As a percentage of NAV

Sector Classification is based on Global Industry Classification Standard (GICS).

INDEX CHARACTERISTICS

Price to Earnings (x)	22.5
Price to Book (x)	3.2
Dividend Yield (%)	1.9

Source: Bloomberg, IBES and Value Partners Malaysia, as at end November 2024.

M & A Value Partners Asset Management Malaysia Sdn. Bhd.

For more information, please contact:



Follow us on:

No. 47-9, The Boulevard Mid Valley City, Lingkaran Syed Putra, 59200, Kuala Lumpur

www.mna-vp.com.my

enquiry@mna-vp.com.my

www.facebook.com/MnA-ValuePartners | www.twitter.com/MA-ValuePartners

VP-DJ Shariah China A-Shares 100 ETF



NOVEMBER 2024

TOP 10 HOLDINGS [^]		Sector [#]	Weighting
300750 C2	Contemporary Amperex Technology Co Ltd A	Industrials	9.3%
<i>Contemporary Amperex is the largest and most advanced electric vehicle (EV) battery provider globally and is a supplier to many top-tier automakers, such as Tesla and Toyota. The company is set to benefit from the increasing penetration of EVs worldwide, especially given its leadership position.</i>			
002594 C2	BYD Company Limited A	Consumer Discretionary	4.1%
<i>BYD is one of the top EV manufacturers in China and has successfully expanded overseas, including the US and Europe. The company is set to grow further as more people, both domestically and abroad, are replacing traditional vehicles with EVs.</i>			
000333 C2	Midea Group Co., Ltd. A	Consumer Discretionary	3.7%
<i>Midea Group manufactures, markets and installs household electrical appliances, compressors, components, provides services in information technology, corporate investment consultation, software and hardware development, property management and engineering supports.</i>			
600276 C1	Jiangsu Hengrui Medicine Co A	Health Care	2.6%
<i>Jiangsu Hengrui develops pharmaceutical products and is a leading player in China's fast-growing oncology market. Its solid pipeline of innovative drugs in China and overseas is a huge driver for market share gains and long-term earnings.</i>			
601088 C1	China Shenhua Energy Co Ltd A	Energy	2.6%
<i>China Shenhua Energy is among the largest coal producers in China. As an integrated company, China Shenhua also draws revenues from its non-coal businesses, including new energy, electricity generation, railway transportation, shipping and others.</i>			
300832 CH	Shenzhen Mindray Bio-Medical Electronics Co Ltd A	Health Care	2.5%
<i>Shenzhen New Industries Biomedical Engineering Co., Ltd. operates as a biomedical company. The Company researches, develops, produces, and sells clinical laboratory instrument and vitro diagnostic reagent. Shenzhen New Industries Biomedical Engineering also offers related technical service.</i>			
601138 C1	Foxconn Industrial Internet Co Ltd A	Information Technology	2.5%
<i>Foxconn Industrial Internet is a global leader in the designing and manufacturing of communications- and cloud-related tools and equipment, such as network switches, routers, smart home gateways, and others. The company benefits from the ongoing adoption of 5G technology globally and, given its leading position, continues to see market share gains.</i>			
688041 C1	Hygon Information Technology Co Ltd A	Information Technology	2.3%
<i>Hygon Information Technology Co., Ltd. manufactures and distributes computer components. The Company produces high end processors, deep computing processors, accelerators, calculator chips, and other related products. Hygon Information Technology markets its products worldwide.</i>			
601816 C1	Beijing-Shanghai High Speed Railway Co Ltd A	Industrials	2.2%
<i>The company operates high-speed railways and stations connecting two major economic zones in China. The railway is one of the busiest in the world and among China's most profitable lines. The company should benefit from traffic recovery as China relaxes its pandemic measures.</i>			
601857 C1	PetroChina Co Ltd A	Energy	2.1%
<i>PetroChina Company Limited operates as an oil and gas company. The Company offers crude oil and oil products exploration, development, production and marketing. PetroChina also markets petrochemical products and derivative chemicals</i>			

[^] As a percentage of NAV. [#] As per GICS classification.

DISCLAIMER: This factsheet is prepared by M & A Value Partners Asset Management Malaysia Sdn. Bhd. ("MAVP") (Formerly known as Value Partners Asset Management Malaysia Sdn Bhd.) Neither Value Partners nor the directors of the company accept any responsibility whatsoever for the accuracy or completeness of the information provided. It should not be copied or distributed to third parties without the written consent of MAVP. The views expressed are the views of MAVP only and are subject to change based on market and other conditions. The information provided does not constitute investment advice and should not be relied on as such. All materials have been obtained from sources believed to be reliable but its accuracy is not guaranteed. This material contains certain statements which may be deemed forward-looking. Please note that any such statements are not guarantee of any future performance and actual results may differ from those projected. The information contained herein does not constitute an offer to sell or an invitation to buy any securities in any jurisdiction in which such distribution or offer is not authorised. No part of this document or any information contained herein may be distributed, reproduced, taken or transmitted into jurisdiction or territories in which such activities are not permitted. Any failure to comply with the restrictions may constitute a violation of the relevant laws. Investors should note that investment involves risk and past performance is not indicative of future results. Investors may not get back the full amount invested. The price of units and distribution payable, if any, may go down as well as up. Past performance of a fund should not be taken as indicative of its future performance. Investors are advised to read and understand the contents of the Prospectus dated 12 July 2021 and First Supplementary Prospectus dated 31 May 2023 which have been duly registered with the Securities Commission Malaysia, before investing. Investors should consider the fees and charges involved, and risk factors of the fund in particular those associated with investing in emerging markets. Investors can obtain a copy of the prospectus from MAVP or its authorised participating dealers. Registration of documents with the Securities Commission of Malaysia does not indicate that the Securities Commission of Malaysia recommends or endorses the product. This material has not been reviewed by the Securities Commission of Malaysia. M & A Value Partners Asset Management Malaysia Sdn. Bhd.